Cargando…
No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
PURPOSE: Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious adverse event associated with a number of drugs, including second- and third-generation cephalosporins. A positive direct antiglobulin test (DAT) is a reliable finding in DIIHA, but positive results without evidence of hemol...
Autores principales: | Hamed, Kamal, Wiktorowicz, Tatiana, Assadi Gehr, Maziar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502402/ https://www.ncbi.nlm.nih.gov/pubmed/32982335 http://dx.doi.org/10.2147/IDR.S268269 |
Ejemplares similares
-
No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]
Publicado: (2020) -
In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022) -
LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
por: Holland, Thomas L, et al.
Publicado: (2022) -
Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022) -
Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)